Valuation : Intra-Cellular Therapies, Inc.

Market Cap 1.4TCr 1.21TCr 1.13TCr 1.03TCr 1.95TCr 1,34000Cr 1.95TCr 13TCr 5.24TCr 68TCr 5.26TCr 5.15TCr 2,24300Cr P/E 2023
-49.2x
P/E 2024 -115x
Enterprise Value 1.3TCr 1.12TCr 1.05TCr 961.53Cr 1.81TCr 1,24600Cr 1.82TCr 12TCr 4.88TCr 63TCr 4.89TCr 4.79TCr 2,08600Cr EV / Sales 2023
13.8x
EV / Sales 2024 11.6x
Free-Float
95.68%
Yield 2023 *
-
Yield 2024 -
3 years 45.5
Extreme 45.5
131.98
5 years 32.31
Extreme 32.31
131.98
10 years 6.75
Extreme 6.75
131.98
Manager TitleAgeSince
Chief Tech/Sci/R&D Officer - 01/04/2022
Compliance Officer 64 02/07/2019
Corporate Secretary - -
Date Insider Type Main position Quantity % Market Cap.
02/04/25 Issuer saleCompany 10,000 0.0094%
02/04/25 Issuer sale

Director

55,511 0.0522%
02/04/25 Issuer sale

Chief Technology Officer

2,65,944 0.2501%
Change 5-day change 1-year change 3-year change Capi.($)
-0.04%-.--%-.--%+140.42% 1.4TCr
-1.67%-4.78%+36.76%-4.34% 7.93TCr
-0.90%+2.39%-19.06%-35.50% 5.92TCr
-3.35%-4.92%+472.81%+18.97% 5.51TCr
-6.78%-4.19%-3.45%+28.35% 4.99TCr
-2.43%-2.35%+8.33%+160.40% 4.79TCr
-1.35%+0.79%+65.25%-18.47% 3.23TCr
-2.64%-2.69%+46.99%+92.55% 2.52TCr
-0.09%+4.98%+11.00%+199.86% 2.39TCr
-0.34%+1.35%+62.33%+122.21% 1.69TCr
Average -1.96%-1.08%+68.10%+70.45% 4.04TCr
Weighted average by Cap. -2.34%-1.98%+80.93%+45.18%

Financials

2023 2024
Net sales 46Cr 40Cr 38Cr 34Cr 65Cr 4.44TCr 65Cr 445.12Cr 173.67Cr 2.24TCr 174.35Cr 170.55Cr 7.43TCr 68Cr 59Cr 55Cr 50Cr 95Cr 6.51TCr 95Cr 652.63Cr 254.63Cr 3.28TCr 255.63Cr 250.06Cr 11TCr
Net income -14Cr -12Cr -11Cr -10Cr -19Cr -1.33TCr -19Cr -133.88Cr -52Cr -673.86Cr -52Cr -51Cr -2.23TCr -7.47Cr -6.43Cr -6.03Cr -5.51Cr -10Cr -713.71Cr -10Cr -72Cr -28Cr -360.28Cr -28Cr -27Cr -1.19TCr
Net Debt -48Cr -41Cr -39Cr -35Cr -67Cr -4.6TCr -67Cr -461.06Cr -179.89Cr -2.32TCr -180.59Cr -176.66Cr -7.69TCr -98Cr -85Cr -80Cr -73Cr -136.73Cr -9.41TCr -137.16Cr -943.29Cr -368.04Cr -4.75TCr -369.47Cr -361.43Cr -16TCr
Logo Intra-Cellular Therapies, Inc.
Intra-Cellular Therapies, Inc. is a biopharmaceutical company focused on the development and commercialization of small molecule drugs that address underserved medical needs primarily in psychiatric and neurological disorders. The Company’s product, CAPLYTA (lumateperone), is an oral, once daily atypical antipsychotic approved in adults for the treatment of schizophrenia and the treatment of depressive episodes associated with bipolar I or II disorder (bipolar depression) as monotherapy and as adjunctive therapy with lithium or valproate. Lumateperone is also being studied for the treatment of major depressive disorder, and other psychiatric and neurological disorders. Its pipeline includes several product candidates in clinical development and additional product candidates in non-clinical testing, such as the ITI-1284-ODT-SL program, Phosphodiesterase type I inhibitor (PDE1) program, ITI-333 program, and ITI-1500 Non-Hallucinogenic Psychedelic program.
Employees
860
Trader
-
Investor
-
Global
-
Quality
-
ESG MSCI
BBB
  1. Stock Market
  2. Stocks
  3. ITCI Stock